阿片类药物在烧伤急性疼痛管理中的现状与未来科学及偏向性配体技术的潜力
严重烧伤疼痛剧烈且临床管理困难,阿片类药物仍是住院烧伤患者药物治疗的主要手段,但患者发生阿片相关不良事件风险高。指南推荐根据生理学、药理学和医师经验选择阿片类药物,并个体化初始治疗及持续调整。本文综述阿片类药物的细胞作用机制,并讨论基于偏向性配体技术开发的静脉用奥利塞定(oliceridine)在重度急性疼痛中的疗效与安全性;其大型3期研究未纳入烧伤患者。
要点
- 阿片类药物仍是烧伤住院患者急性疼痛药物治疗的有效主要手段。
- 指南推荐依据生理学、药理学和医师经验选择阿片类药物,并个体化调整。
- 奥利塞定基于偏向性配体技术开发,其大型3期研究未纳入烧伤患者。
核心结论
- 阿片类药物仍是烧伤住院患者急性疼痛药物治疗的有效主要手段。
- 指南推荐阿片类药物选择应基于生理学、药理学和医师经验,并个体化初始治疗及持续调整。
- 奥利塞定基于偏向性配体技术开发,已评估用于中度至重度急性疼痛,但大型3期研究未纳入烧伤患者。
研究设计与样本
- 本文为综述,回顾阿片类药物在细胞层面的作用及其与伤害感受和阿片相关不良事件的关系。
- 综述讨论最近获批的静脉用阿片类药物奥利塞定(oliceridine)的临床疗效与安全性。
主要发现
- 严重烧伤相关疼痛剧烈且临床管理困难,损伤炎症相关的代谢失衡及换药、清创、切除和移植等治疗干预可进一步加重疼痛。
- 烧伤后疼痛复杂、损伤特征及常见人口学特征使患者处于阿片相关不良事件高风险。
- 尽管非阿片药物和非药物辅助治疗取得进展,最佳方案仍缺乏显著证据支持,仍需评估新疗法。
- 奥利塞定基于偏向性配体技术开发,已评估用于中度至重度急性疼痛,但大型3期研究未纳入烧伤患者。
关键数值与推荐
- 指南推荐阿片类药物选择应基于生理学、药理学和医师经验,并个体化初始治疗及持续调整。
临床怎么用
- 指南推荐阿片类药物选择应基于生理学、药理学和医师经验,并个体化初始治疗及持续调整。
- 作者讨论了奥利塞定用于烧伤相关疼痛的潜在意义和未来研究方向。
局限性
- 奥利塞定的大型3期研究未纳入烧伤患者。
- 最佳方案仍缺乏显著证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pain associated with severe burn injury is one of the most intense and clinically challenging to manage, as the metabolic imbalances associated with the inflammation caused by the injury and treatment interventions (e.g., dressing changes and debridement, excision, and grafting) can further worsen the pain. In the pharmacologic management of a complex, hospitalized patient with burn injuries, opioid therapy remains an efficacious mainstay of treatment. However, the complex nature of pain, injury characteristics, and common demographics after burn injury place patients at high risk of opioid-related adverse events. Thus, guidelines recommend that decisions about choice of opioid be based on physiology, pharmacology, and physician experience, in addition to individualizing initial treatment with subsequent continual adjustments throughout care. Although substantial progress has been made in pain management strategies with utilization of nonopioid medications and nonpharmacologic adjuncts to opioid pharmacotherapy, there is still a need to evaluate new therapies, as an optimal regimen still lacks significant evidential support. Herein, we review the actions of opioids at the cellular level, contributing to both nociception and opioid-related adverse events. We also discuss the most recently approved intravenously administered opioid, oliceridine, developed utilizing biased ligand technology, including a summary of its clinical efficacy and safety in the management of severe acute pain. While oliceridine has been evaluated for the management of moderate-to-severe acute pain, the large phase 3 studies did not include patients with burn injuries. However, potential implications and future study direction for pain associated with burn injury are discussed.
引用
- Hill DM, DeBoer E. State and Future Science of Opioids and Potential of Biased-ligand Technology in the Management of Acute Pain After Burn Injury. J Burn Care Res. 2023. PMID: 36638083. doi:10.1093/jbcr/irad004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。